A new era in the treatment of multiple sclerosis

S.A. Broadley, M.H. Barnett, M. Boggild, B.J. Brew, H. Butzkueven, R. Heard, S. Hodgkinson, Allan Kermode, J. Lechner-Scott, R.A. Macdonell, M. Marriott, D.F. Mason, J. Parratt, S.W. Reddel, C.P. Shaw, M. Slee, J.M. Spies, B.V. Taylor, W.M. Carroll, T.J. KilpatrickJ. King, P.A. Mccombe, J.D. Pollard, E. Willoughby

    Research output: Contribution to journalArticle

    8 Citations (Scopus)


    © 2015 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.
    Original languageEnglish
    Pages (from-to)139-141
    JournalMedical Journal of Australia
    Issue number3
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'A new era in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

    Cite this